GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » ROC (Joel Greenblatt) %

Viva Biotech Holdings (HKSE:01873) ROC (Joel Greenblatt) % : -0.41% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Viva Biotech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.41%.

The historical rank and industry rank for Viva Biotech Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:01873' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41.48   Med: 56.61   Max: 194.52
Current: 5.55

During the past 8 years, Viva Biotech Holdings's highest ROC (Joel Greenblatt) % was 194.52%. The lowest was -41.48%. And the median was 56.61%.

HKSE:01873's ROC (Joel Greenblatt) % is ranked better than
84.51% of 1459 companies
in the Biotechnology industry
Industry Median: -333.95 vs HKSE:01873: 5.55

Viva Biotech Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Viva Biotech Holdings ROC (Joel Greenblatt) % Historical Data

The historical data trend for Viva Biotech Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings ROC (Joel Greenblatt) % Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 148.20 -41.48 31.57 -11.24 5.42

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.50 2.18 -24.43 10.95 -0.41

Competitive Comparison of Viva Biotech Holdings's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Viva Biotech Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's ROC (Joel Greenblatt) % falls into.



Viva Biotech Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(378.125 + 303.531 + 441.634) - (889.571 + 0 + 59.471)
=174.248

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(431.549 + 284.062 + 255.16) - (595.572 + 0 + 40.72)
=334.479

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Viva Biotech Holdings for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.984/( ( (2094.196 + max(174.248, 0)) + (1816.699 + max(334.479, 0)) )/ 2 )
=-8.984/( ( 2268.444 + 2151.178 )/ 2 )
=-8.984/2209.811
=-0.41 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (HKSE:01873) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Viva Biotech Holdings ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines